Structure Therapeutics Inc. (GPCR) Form 10-Q — Aug 6, 2026

Key figures

Net Income

-$182.1 million (net loss, six months ended June 30, 2026; vs. -$108.5 million in the six months ended June 30, 2025)

Total Assets

1425415000

Cash Position

$1,342.7 million (cash, cash equivalents and short-term investments as of June 30, 2026; cash and equivalents alone were $272.6 million)

Shares Outstanding

213929572

Cash runway

sufficient to fund projected operations and key clinical milestones through the end of 2028, excluding pre-commercialization costs including commercial manufacturing

Accumulated deficit

$652.4 million as of June 30, 2026

Atm sept 2025 sales

3,040,000 ADSs for gross proceeds of approximately $58.5 million

Atm remaining capacity

$341.5 million of $400.0 million aggregate

Product revenue to date

0

Ole discontinuation rate

10.4% favorable overall discontinuation rate

Access 2 weight loss 44wk

16.3% placebo-adjusted at 180 mg and 16.0% at 240 mg

Genentech upfront payment

$100.0 million received in Q1 2026 under the December 2025 GNE Agreement

Access 2b weight loss 36wk

11.3% placebo-adjusted at 120 mg

Schrodinger milestones paid

$9.0 million of up to $89.0 million under the Aconcagua-Schrodinger Agreement

Phase3 accomplish 1 enrollment

up to 3,600 patients

Phase3 accomplish 2 enrollment

up to 1,100 patients

Follow on net proceeds dec 2025

$701.5 million net from 9,961,538 ADSs priced at $65.00 per ADS

Price after filing

Close on the filing date to close N calendar days later (from $49.64). Historical, not a forecast.